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Abstract
Background: Specific differences in signaling and antiviral properties between the different Lambda-interferons, a novel
group of interferons composed of IL-28A, IL-28B and IL-29, are currently unknown. This is the first study comparatively
investigating the transcriptome and the antiviral properties of the Lambda-interferons IL-28A and IL-29.
Methodology/Principal Findings: Expression studies were performed by microarray analysis, quantitative PCR (qPCR),
reporter gene assays and immunoluminometric assays. Signaling was analyzed by Western blot. HCV replication was
measured in Huh-7 cells expressing subgenomic HCV replicon. All hepatic cell lines investigated as well as primary
hepatocytes expressed both IFN-l receptor subunits IL-10R2 and IFN-lR1. Both, IL-28A and IL-29 activated STAT1 signaling.
As revealed by microarray analysis, similar genes were induced by both cytokines in Huh-7 cells (IL-28A: 117 genes; IL-29:
111 genes), many of them playing a role in antiviral immunity. However, only IL-28A was able to significantly down-regulate
gene expression (n = 272 down-regulated genes). Both cytokines significantly decreased HCV replication in Huh-7 cells. In
comparison to liver biopsies of patients with non-viral liver disease, liver biopsies of patients with HCV showed significantly
increased mRNA expression of IL-28A and IL-29. Moreover, IL-28A serum protein levels were elevated in HCV patients. In a
murine model of viral hepatitis, IL-28 expression was significantly increased.
Conclusions/Significance: IL-28A and IL-29 are up-regulated in HCV patients and are similarly effective in inducing antiviral
genes and inhibiting HCV replication. In contrast to IL-29, IL-28A is a potent gene repressor. Both IFN-ls may have
therapeutic potential in the treatment of chronic HCV.
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Introduction
Recently, several novel cytokines of the IL-10-like cytokine
family have been discovered, including interferon (IFN)-ls [1,2].
IFN-ls comprise three distinct genes: IFNl1 (IL29), IFNl2 (IL28A),
and IFNl3 (IL28B) [1,2]. IL-28A and IL-28B proteins are 95%
identical while IL-29 shares only 80% amino acid identity with IL-
28A or IL-28B. Structurally, IFN-ls are related to IL-10 and other
members of the IL-10-like family such as IL-22 [3], which has
recently shown to confer hepatoprotection [4–5]. As IL-28A, IL-
28B and IL-29 functionally resemble type I IFNs (IFN-a/b), they
are also considered as a novel group of IFNs (type III IFNs). Like
IFN-a or IFN-b, IFN-ls exhibit activity against a broad range of
viruses such as encephalomyocarditis virus (EMCV) or vesicular
stomatitis virus (VSV) [1,2], human immunodeficiency virus
(HIV1) [6], Apeu virus [7], cytomegalovirus (CMV) [8], and
herpes simplex virus (HSV) [9]. It has also been shown that they
inhibit HCV replication [10,11]. In contrast, we could recently
demonstrate that IL-22 is not efficient against hepatitis C virus
(HCV) infection [12].
IFN-ls signal through a receptor complex comprised of IL-
10R2 and a unique subunit, IFNl-R1. While IL-10R2 is widely
expressed on a number of different cell types including
hematopoietic cells, expression of the specific receptor IFNl-R1
is more restricted, e.g., it seems to be weakly expressed on
leukocytes. As signaling through the type-I-interferon receptor,
signaling through the IFN-l receptor results in the activation of
signal transducer and activator of transcription (STAT)-1 and
STAT2. Together with an accessory factor, IFN regulatory factor
9 (IRF-9; p48), STAT1 and STAT2 form the transcription factor
IFN-stimulated gene factor-3 (ISGF3) which translocates to the
nucleus to initiate the induction of target genes [1].
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Like type I IFNs, IFN-ls are strongly induced by double
stranded (ds) RNA or viral infection, suggesting common
regulatory factors. In fact, it has recently been demonstrated that
the IL29 gene, similar to the gene encoding IFN-b, is regulated by
virus-activated IRF3 and IRF7. In contrast, IL28A and IL28B
gene expression is mainly controlled by IRF7, similar to the gene
encoding IFN-a [13].
Although the antiviral effects of IL-28A and IL-29 have been
compared with IFN-a, IFN-b and IFN-c regarding their antiviral
and gene-inducing activities [7,14,15,16,17], there are very limited
data directly comparing signaling and antiviral properties of IL-
28A and IL-29. Therefore, in this study, we directly compared
these two cytokines regarding their signal transduction, target gene
expression profiles, antiviral properties against HCV and their
expression in different human liver diseases.
Materials and Methods
Reagents
Recombinant human IL-28A, IL-29 and IFN-a were purchased
from R&D Systems (Minneapolis, MN). Antibodies were from BD
Transduction Laboratories, Franklin Lakes, NY (pSTAT1),
Upstate Biotechnology, Lake Placid, NY (pSTAT3), and Santa
Cruz Biotechnology, Santa Cruz, CA (STAT1, STAT3). Horse-
radish peroxidase conjugated secondary antibodies to mouse or
rabbit IgG and chemiluminescent substrate (SuperSignal West
Dura Extended Duration Substrate) were from Pierce (Rockford,
IL).
Cell culture
The human hepatic cancer cell lines HepG2, Hep3B and Huh-
7 were obtained from American Type Culture Collection (Rock-
ville, MD) and were grown in DMEM medium with 10% fetal calf
serum (PAA, Pasching, Austria), 1% penicillin/streptomycin (PAA)
in a 5% CO2 atmosphere. Huh-7 cells containing subgenomic
HCV replicons I389luc-ubi-neo/NS3-3/5.1 (Huh 5-2) were
described previously [18,19,20,21]. G418 (Geneticin; Gibco) was
added at a final concentration of 250 mg/ml to HCV replicon-
expressing cells. Primary hepatocytes from human donors were
isolated and cultured as previously described [22].
Isolation of leukocytes, peripheral blood mononuclear
cells (PBMC) and granulocytes
White blood cells were isolated from fresh human anti-
coagulated blood. For the isolation of total leukocytes, 5 ml of
erythrocyte lysis buffer were added to 1 ml of blood. Following
erythrocyte lysis and washing steps with PBS, the leukocytes were
pelleted by centrifugation. For the isolation of PBMCs and
granulocytes, a 6% dextran solution (molecular weight 250.000)
was added to whole blood to precipitate the erythrocytes. The
supernatant containing the white blood cells was treated with lysis
buffer to remove any residual erythrocytes. Following washing
steps, the cell suspension was layered onto a Ficoll-Hypaque
density gradient and centrifuged at 4006g for 30 minutes to
separate mononuclear cells from granulocytes.
Reverse transcriptase polymerase chain reaction (RT-PCR)
and quantitative PCR
Trizol reagent (Invitrogen, Karlsruhe, Germany) was used to
isolate total cellular RNA. Reverse transcription of 2 mg RNA to
cDNA was performed with Omniscript reverse transcriptase
(Qiagen, Hilden, Germany). PCR cycling was run as follows: 40
cycles of denaturing at 95uC for 30 sec, annealing at 60uC for
30 sec, extension at 72uC for 30 sec. Real-time quantitative PCR
was carried out using the Quantitect SYBR Green PCR Kit from
Qiagen (Hilden, Germany) in an ABI Prism 7700 Sequence
Detection System (Applied Biosystems, Darmstadt, Germany).
Oligonucleotide primer pairs (MWG Biotech, Ebersberg, Ger-
many) were designed according to the published sequences
avoiding amplification of genomic DNA and are listed in Table 1.
Luciferase assay
HepG2 cells were transiently transfected with either a 2970 nt
human OAS1 promoter - luciferase construct or a 2553/+10
human MX1 promoter - luciferase construct, both in a pGL2-BV
vector, using SuperfectH (Qiagen, Hilden, Germany), as recently
described [23]. Transfection efficiency was verified by b-
galactosidase assay in all experiments.
Gel electrophoresis and immunoblotting
Cells were solubilized in lysis buffer consisting of 20 mM Tris-
HCl (pH 7.4), 150 mM NaCl, 2 mM EDTA, 2 mM EGTA, 1%
Nonidet P-40, 2 mM phenylmethylsulfonyl fluoride, a protease
inhibitor cocktail (Roche, Mannheim, Germany) and phosphatase
inhibitors (400 mM sodium orthovanadate and 4 mM NaF). Cell
lysates were passed six times through a 21 G needle. After chilling
on ice for 30 minutes, lysates were cleared by centrifugation for 20
minutes at 10,000 g. The Bradford method was used to quantify
the protein concentration of each sample. Immunoblotting was
performed as previously described [24].
Anti-HCV assay in Huh 5-2 cells
Huh 5-2 cells (‘‘HCV-Huh-7’’) were seeded in 6-well plates at a
density of 26105 per well in complete DMEM. Following
incubation for 24 hours at 37uC (5% CO2), medium was replaced
Table 1. Primers used for PCR and quantitative PCR.
Gene Primer combination
IL-10R2 59-GGCTGAATTTGCAGATGAGCA-39
59-GAAGACCGAGGCCATGAGG-39
IFNl-R1 59-ACCTATTTTGTGGCCTATCAGAGCT-39
59-CGGCTCCACTTCAAAAAGGTAAT-39
IL-28 59-AGGGCCAAAGATGCCTTAGA-39
59-TCCAGAACCTTCAGCGTCAG-39
IL-29 59-GGACGCCTTGGAAGAGTCAC-39
59-AGCTGGGAGAGGATGTGGT-39
OAS1 59-ATTGACAGTGCTGTTAACATCATC-39
59-AGATCAATGAGCCCTGCATAAACC-39
MX1 59-AGATCCAGGACCAGCTGAGCCTGT-39
59-GTGGAACTCGTGTCGGAGTCTGGTA-39
GAPDH 59-CGGAGTCAACGGATTTGGTCGTAT-39
59-AGCCTTCTCCATGGTGGTGAAGAC-39
b-actin 59-GCCAACCGCGAGAAGATGA-39
59-CATCACGATGCCAGTGGTA-39
IL-28 (mouse) 59-AGGGTGCCATCGAGAAGAG-39
59-GTGGTCAGGGCTGAGTCATT-39
GAPDH (mouse) 59-CGTCCCTGAGACAAAATGGT-39
59-TCTCCATGGTGGTGAAGACA-39
doi:10.1371/journal.pone.0015200.t001
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with 2 ml DMEM supplemented with IL-28A, IL-29 or IFN-a.
After further incubation at 37uC for 72 hours, cell culture medium
was removed and luciferase activity was determined using a Lumat
LB9507 luminometer (Berthold, Freiburg, Germany) as described
recently [21].
IL-28A immunoluminometric assay (ILMA)
For quantification of IL-28A in human serum samples, Human
IL-28A/IFN-lambda 2 DuoSet (R&D Systems, Wiesbaden,
Germany) was used to develop an IL-28A-specific immunolumi-
nometric assay. The detection limit was 4.9 pg/ml. Signal
detection was performed with a biotinylated detection antibody
and incubation with neutravidin-HRP and the chemoluminescent
substrate Femtoglow (Michigan Diagnostics, Troy, MI).
Murine cytomegalovirus (MCMV) infection in vivo
16106 plaque-forming units of MCMV of the Smith strain [25]
in PBS were injected intravenously into C57/BL6 mice as
described previously [8]. Control mice got an injection of PBS
only. After 45 h, mice were euthanized by CO2 inhalation, and
the livers were collected and homogenized in Trizol reagent to
isolate total RNA. The study was approved by the Animal Care
and Use Committee of the State of Bavaria (Regierung von
Oberbayern, approval ID 209.1/211-2531-18/03) according to
the National Institutes of Health ‘‘Guide for the Care and Use of
Laboratory Animals’’.
Sampling of human liver biopsy tissue, blood and serum
samples including Ethics statement
Human liver biopsy tissue was obtained from patients undergoing
diagnostic liver biopsy for medical reasons such as staging of chronic
hepatitis C. The study was approved by the Ethics committee of the
Ludwig-Maximilians-University Munich (Department of Medicine,
Munich-Grosshadern) and adhered to the ethical principles for
medical research involving human subjects of the Helsinki
Declaration (http://www.wma.net/e/policy/b3.htm). All partici-
pating patients gave written, informed consent prior to liver biopsy
sampling. A 3 mm long piece of the biopsy cylinder was
immediately stored in Trizol reagent and RNA was isolated as
described previously [26]. Human blood and serum samples were
obtained after written informed consent from patients and controls
and were stored at 280uC until further analysis.
Microarray analysis
After reaching 70% confluency, Huh-7 cells were incubated
overnight with serum-reduced medium containing 1% FCS. The
next day, cells were stimulated in triplicates with 100 ng/ml IL-
28A, IL-29 or left unstimulated. RNA was isolated at the indicated
time points using the RNeasy kit from Qiagen (Hilden, Germany).
For the analysis of the cytokine-induced gene expression, Agilent
Whole Human Genome Oligo Microarrays were used in
combination with a One-Color based hybridization protocol.
Signals on the microarrays were detected with the Agilent DNA
Microarray Scanner. Differential gene expression was identified
within the human cells by applying appropriate biostatistics to the
data set. GeneSpring GX 10 analysis software (Agilent Technol-
ogies, Santa Clara, CA) was used to normalize and analyze the
raw data. Cytokine-induced gene expression was calculated in
comparison to unstimulated cells at the same time points. Welch’s
approximate t-test (‘‘unpaired unequal variance’’, parametric) was
applied to the comparison of the different groups. Resulting p-
values were corrected for multiple testing using the algorithm of
Benjamini and Hochberg [27]. Functional analysis (categories of
biological processes, molecular functions and pathway categories)
of induced and repressed genes was performed using the Panther
software [28]. By comparing cytokine-regulated gene identification
numbers (IDs) to the distribution of all gene IDs represented on
the Whole Human Genome Oligo Microarray (Agilent Technol-
ogies), it was calculated whether a specific class is over- or
underrepresented. P-values of p,1025 (based on binomial test)
were considered as a sign of manifest enrichment in the context of
a Panther analysis for biological processes, molecular functions
and pathway categories. All microarray data presented are
MIAME compliant and the raw data have been deposited in a
MIAME compliant database in MIAMExpress (available at www.
ebi.ac.uk/microarray/, accession number E-MEXP-2861) as
detailed on the MGED Society website http://www.mged.org/
Workgroups/MIAME/miame.html.
Statistical analysis
Statistical analysis was performed by using two-tailed Student’s
t-test. P levels,0.05 were considered as statistically significant.
Standard errors of the mean (SEM) were calculated by dividing
the standard deviation (SD) by the square root of the number of
single data in the respective group.
Results
Hepatic cells express the IFN-l receptor complex
In order to utilize a hepatic cell model to study the IFN-l
ligand-receptor system, we first confirmed that the IFN-l receptor
subunits IL-10R2 and IFNl-R1 are present in hepatic cells. RT-
PCR analysis demonstrated IL-10R2 and IFNl-R1 mRNA
expression in several human hepatic cancer derived cell lines
(HepG2, Hep3B, Huh-7) as well as in HCV replicon expressing
Huh-7 5-2 cells and Huh-7 cells cured from HCV by IFN-a and
IFN-c (HCV-cured Huh-7) (Fig. 1A). Primary hepatocytes from
two different donors also expressed mRNA for both IFN-l
receptor subunits (Fig. 1A) while leukocytes show only low
expression (Fig.1A). The prostate cancer cell line LNCaP was
used as a negative control for IFNl-R1 expression. Quantitative
PCR analyses including total leukocytes as well as peripheral blood
mononuclear cells (PBMC) and granulocytes from four different
donors revealed that leukocytes express only 5.561.8% of the level
or IFN-lR1 in comparison to Huh-7 cells (Fig. 1B). Among the
leukocytes, expression of IFN-lR1 was 1.960.5-fold higher in
PBMC than in granulocytes (Fig. 1B). IL-10R2 mRNA expression
was higher in leukocytes compared to liver cells (Fig. 1C), and
granulocytes had a 1.760.1-fold higher IL-10R2 expression than
PBMC.
IFN-ls induce STAT1 but not STAT3 phosphorylation
Previous studies in other cell systems reported activation of
STAT signaling by IFN-ls [1,14]. Therefore, we investigated the
influence of IL-28A and IL-29 on phosphorylation levels of
STAT1 and STAT3 in naı¨ve Huh-7 cells. As demonstrated in
Fig. 2A, both cytokines activated STAT1 whereas IL-29 had a
stronger effect than IL-28A. On the other hand, STAT3 was not
activated by IL-28A and stimulation with IL-29 had only minor
effects (Fig. 2B).
IL-28A and IL-29 induce expression of similar genes in
Huh-7 cells but differ in their gene down-regulating
abilities
Next, we analyzed by microarray experiments the IFN-l-
induced gene expression in hepatic cells. Naı¨ve Huh-7 cells were
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stimulated for 6 hours with 100 ng/ml IL-28A or IL-29, while
controls were left unstimulated for the same time interval.
Altogether, a total number of 389 genes were influenced equal
to or more than two-fold by IL-28A (117 genes up-regulated, 272
down-regulated) and a total number of 115 genes by IL-29 (111
genes up-regulated, 4 down-regulated), respectively (p,0.01
without correction for multiple testing) (Table 2). When applying
more stringent criteria (adjusted p-values [adj.-p],0.05; corrected
for multiple testing by the Benjamini and Hochberg algorithm
[27]), a total of 154 genes was significantly regulated by IL-28A (65
genes up-regulated, 89 down-regulated) and only 3 genes were
significantly regulated by IL-29 (all up-regulated). The top 20 hits
of up-regulated genes were identical for both cytokines although in
a slightly different order (Table 3). The gene that was most
induced by both cytokines was MX1 which was increased 167.0-
and 183.4-fold by IL-28A and IL-29, respectively.
Furthermore, IL-28A stimulation resulted in an at least two-fold
decreased expression of a multitude of genes (272 genes for
p,0.01 without multiple testing adjustment; 89 genes for adj.-
p,0.05) with up to 9.3-fold reduced levels (Table 4).
We then analyzed the induced and repressed genes for specific
enrichment of defined biological processes and molecular
functions using the Panther database [28]. The genes activated
by IL-28A and IL-29 comprised genes of immunity and defense
(p = 5.7610217 for IL-28A, p = 2.5610216 for IL-29 vs. distribu-
tion of all genes on the microarray chip), especially interferon-
mediated antiviral immunity (p = 2.161027 for IL-28A,
p = 1.861026 for IL-29) and proteolysis (IL-28A only,
p = 3.861026) (Table 5; Fig. S1A). Genes of the molecular
function class of ligase (p = 3.761026 for IL-28A, p = 8.261027
for IL-29) and its subgroup ubiquitin protein ligase (p = 8.661027
for IL-28A, p = 1.161026 for IL-29) were significantly enriched
(Table 5; Fig. S1B).
Amongst the downregulated genes following IL-28A stimula-
tion, those involved in the biological process of mRNA
transcription regulation were especially enriched (p = 1.261026;
Table 5; Fig. S2A). Additionally, analysis revealed a down-
regulation in the molecular function class of nucleic acid binding
proteins (p = 1.361027) with its subclass ‘‘other DNA-binding
proteins’’ (p = 2.561029; Table 5; Fig. S2B). Moreover, homeobox
transcription factors, a subclass of the transcription factor group,
were significantly enriched (p = 2.361027; Table 5 and Fig. S2B).
In contrast, IL-29 reduced gene expression of only four genes
more than two-fold (p,0.01; data not shown). However, when
corrected for multiple testing, none of these regulations remained
significant (adj.-p.0.05; data not shown).
In addition, we analyzed gene expression after three hours of
stimulation with IL-28A or IL-29, respectively. The overall
number of genes regulated more than two-fold was much lower
than after 6 hours (IL-28A: 16 genes up-regulated, 0 down-
Figure 2. IL-28A and IL-29 strongly activate STAT1 but not
STAT3 in naı¨ve Huh-7 cells. Activation and expression of phospho-
STATs and protein loading of the respective STAT proteins were
assessed by immunoblotting. (A) Phospho-STAT1 activation after
15 min of stimulation with IL-28A and IL-29 (100 ng/ml). (B) STAT3 is
phosphorylated only to a low extent by stimulation with IL-29 but not
with IL-28A. One representative experiment (n = 3) is shown.
doi:10.1371/journal.pone.0015200.g002
Table 2. Summary for the number of up- and down-
regulated genes after 6 hours applying different stringency
criteria.
p#0.01 adj.-p#0.05
FC$2 FC$2
up down S up down S
IL-28A vs.
untreated
117 272 389 65 89 154
IL-29 vs.
untreated
111 4 115 3 0 3
The left group represents hits from the initial screening with uncorrected
p-value of #0.01 vs. untreated cells. The right group depicts the number of
regulated genes after the p-value was adjusted for multiple testing. FC = fold-
change.
doi:10.1371/journal.pone.0015200.t002
Figure 1. The IFN-l receptor complex consisting of IL-10R2 and IFNl-R1 is expressed in hepatic cell lines. (A) Expression of IL-10R2 and
IFNl-R1 in various hepatic cell lines, primary hepatocytes from two different donors and primary leukocytes were analyzed by RT-PCR analysis of
mRNA derived from cells as indicated. The prostate cancer cell line LnCaP was used as a negative control for IFNl-R1 expression. (B) Quantitative PCR
analysis reveals a much lower expression of IFNl-R1 mRNA in leukocytes from four different donors in comparison to liver cells. PBMC express twice
as much IFN-lR1 than granulocytes. Expression data are normalized to Huh-7 cells. (C) IL-10R2 was expressed at higher levels in leukocytes in
comparison to hepatic cells. Data are normalized to the expression in Huh-7 cells.
doi:10.1371/journal.pone.0015200.g001
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regulated; IL-29: 39 genes up-regulated, 14 down-regulated). After
correction for multiple testing, only two genes remained
significantly up-regulated by IL-29 (MX1 and IFIT1) while IL-
28A had no significant effect on gene expression (data not shown).
Validation of the microarray data by quantitative PCR
and luciferase assay
In the next set of experiments, we verified the IFN-l induced
gene expression in naı¨ve Huh-7 cells by quantitative RT-PCR in
an independent set of RNA samples at different time points. In this
analysis, we included the most strongly induced genes for both
cytokines (MX1; Table 3) and additionally analyzed expression of
OAS1, coding for another important antiviral protein (29,59-OAS)
regulated by IL-28A and IL-29 (32.2- and 41.0-fold, respectively;
Table 3).
The results are depicted in Figure 3 and show a significant
increase in OAS1 mRNA expression of more than 2800-fold
following IL-28A and more than 5000-fold by IL-29 stimulation
after 24 hours (Fig. 3A). MX1 mRNA expression was induced up
to 95-fold by IL-28A and 78-fold by IL-29 (Fig. 3B). While MX1
reached maximal expression levels after 9 hours, OAS1 was
induced most strongly after 24 hours (Fig. 3A, B).
To analyze possible additive/synergistic effects of IL-28A and
IL-29, Huh-7 cells were stimulated with either cytokine alone (at a
concentration of 100 ng/ml) or with a combination of both
cytokines together (50 ng/ml each and 100 ng/ml each). As
shown in Figure 3C, no significant difference was observed
between the different treatments.
We next aimed to confirm our data in another hepatic cell line
(HepG2) using a luciferase promoter assay as an additional
experimental approach to determine the influence of IFN-ls on
the transcriptional regulation of these two antiviral genes.
Promoter activity of a human –970 nt OAS1 promoter-luciferase
construct and of a 2553/+10 human MX1 promoter-luciferase
construct were examined, following incubation of HepG2 cells
with 100 ng/ml IL-28A and IL-29. OAS1 promoter activity was
significantly stimulated 5.1-fold and 14.3-fold, respectively, above
baseline by treatment with IL-28A and IL-29 for 6 hrs (Fig. 3D;
p,0.0005). MX1 promoter activity was increased 2.4-fold and
4.8-fold by IL-28A and IL-29, respectively (Fig. 3D; p,0.05).
IFN-ls decrease HCV replication in vitro
To investigate whether the activation of genes encoding the
antiviral proteins 29,59-OAS and MX1 results in antiviral activity
in vitro, we analyzed the effect of IL-28A and IL-29 on the HCV
replication rate in HCV replicon expressing Huh-7 cells. In these
experiments, both IL-28A and IL-29 (100 ng/ml) significantly
decreased HCV replication in Huh-7 cells by 84.8% and 87.7%,
Table 3. Overview of the 20 genes whose expression was most strongly induced (p,0.01) by IL-28A and IL-29 in Huh-7 cells after
6 hours of stimulation.
Gene ID Gene symbol Description
IL-28A treatment
fold increase
IL-29 treatment
fold increase
Ratio IL-28A/
IL-29
NM_002462 MX1 Homo sapiens myxovirus (influenza virus) resistance 1 167.0 183.4 0.91
NM_001548 IFIT1 Homo sapiens interferon-induced protein with
tetratricopeptide repeats
89.7 99.8 0.90
NM_022168 IFIH1 Homo sapiens interferon induced with helicase C domain 1 48.3 58.7 0.82
NM_002534 OAS1 Homo sapiens 29,59-oligoadenylate synthetase 1 32.2 41.0 0.79
NM_022873 IFI6 Homo sapiens interferon, alpha-inducible protein 6 (6–16) 28.5 31.8 0.90
NM_003733 OASL Homo sapiens 29,59-oligoadenylate synthetase-like 27.2 35.5 0.77
NM_004335 BST2 Homo sapiens bone marrow stromal cell antigen 2
(Tetherin)
26.0 28.2 0.92
NM_001549 IFIT3 Homo sapiens interferon-induced protein with
tetratricopeptide repeats 3
25.1 29.4 0.85
BG547557 CMPK2 Homo sapiens cytidine monophosphate (UMP-CMP)
kinase 2, mitochondrial
21.9 22.1 0.99
NM_003641 IFITM1 Homo sapiens interferon induced transmembrane
protein 1 (9–27)
20.9 26.8 0.78
NM_033255 EPSTI1 Homo sapiens epithelial stromal interaction 1 (breast) 18.5 19.4 0.95
NM_017631 DDX60 Homo sapiens DEAD (Asp-Glu-Ala-Asp) box polypeptide 60 18.1 20.4 0.89
NM_006187 OAS3 Homo sapiens 29-59-oligoadenylate synthetase 3 17.7 19.7 0.90
NM_006084 IRF9 Homo sapiens interferon-stimulated transcription
factor 3, gamma
17.1 15.2 1.13
NM_001547 IFIT2 Homo sapiens interferon-induced protein with
tetratricopeptide repeats 2
15.3 19.3 0.79
NM_017654 SAMD9 Homo sapiens sterile alpha motif domain containing 9 15.0 16.7 0.90
NM_000593 TAP1 Homo sapiens transporter 1, ATP-binding cassette,
sub-family B (MDR/TAP)
12.1 14.6 0.83
NM_030641 APOL6 Homo sapiens apolipoprotein L 6 11.5 12.3 0.93
NM_080657 RSAD2 Homo sapiens radical S-adenosyl methionine domain
containing 2
10.3 13.9 0.74
NM_005101 ISG15 Homo sapiens ISG15 ubiquitin-like modifier 9.4 10.8 0.87
doi:10.1371/journal.pone.0015200.t003
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respectively (**p,9610215 vs. untreated; IFN-a: 72.5% reduction
vs. untreated, **p,5610213, Fig. 4). At a cytokine concentration
of 10 ng/ml, IL-29 had significantly stronger inhibitory effects on
HCV replication (reduction of 83.4%) than IL-28A (reduction of
70.1%; p,0.005).
IL-28A and IL-29 mRNA and protein expression is
increased in the liver tissue and serum of patients with
HCV infection
Having shown that IFN-ls inhibit HCV replication, we next
analyzed IFN-l expression in viral infection in vivo. First, we
Table 4. Overview of the 20 genes whose expression was most strongly repressed (p,0.01) by IL-28A in Huh-7 cells after 6 hours
of stimulation.
Gene ID Gene symbol Description
IL-28A treatment
fold decrease
NM_018027 FRMD4A Homo sapiens FERM domain containing 4A 29.33
NM_000721 CACNA1E Homo sapiens calcium channel, voltage-dependent, R type, alpha 1E subunit 28.82
X94553 FOXE1 Homo sapiens forkhead box E1 (thyroid transcription factor 2) 28.37
THC2559929 SNC73 Q9UP60_HUMAN (Q9UP60) SNC73 protein 27.65
NM_080819 GPR78 Homo sapiens G protein-coupled receptor 78 25.47
NM_198390 CMIP Homo sapiens c-Maf-inducing protein 25.36
AB014771 MOP-1 Homo sapiens MOP-1 25.16
THC2678411 THC2678411 Q34Z38_9GAMM (Q34Z38) Outer membrane efflux protein precursor 24.84
AF490258 FBRSL1 Homo sapiens fibrosin-like 1 24.74
NM_021569 GRIN1 Homo sapiens glutamate receptor, ionotropic, N-methyl D-aspartate 1 24.51
NM_032805 ZSCAN10 Homo sapiens zinc finger and SCAN domain containing 10 24.32
Y10152 Y10152 Homo sapiens CRF2 receptor, beta isoform, aberrantly spliced, (94bp deletion) 24.44
NM_004054 C3AR1 Homo sapiens complement component 3a receptor 1 24.26
NM_003961 RHBDL1 Homo sapiens rhomboid, veinlet-like 1 (Drosophila) 24.22
NM_019105 TNXB Homo sapiens tenascin XB (TNXB), transcript variant XB 24.08
NM_013271 PCSK1N Homo sapiens proprotein convertase subtilisin/kexin type 1 inhibitor 23.98
NM_033120 NKD2 Homo sapiens naked cuticle homolog 2 (Drosophila) 23.90
NM_001003845 SP5 Homo sapiens Sp5 transcription factor 23.72
NM_000554 CRX Homo sapiens cone-rod homeobox 23.71
AF335478 KLK3 Homo sapiens prostate-specific antigen variant 2 23.60
doi:10.1371/journal.pone.0015200.t004
Table 5. Functional classification of IL-28A and IL-29-induced and repressed genes regarding the categories of biological
processes and molecular functions applying the Panther software [28].
Enrichment class:
biological processes
induced by IL-28A
(p-value)
induced by IL-29
(p-value)
Immunity and defense 1.861026 2.161027
Interferon-mediated immunity 5.7610217 2.561026
Proteolysis 3.861026 n. s.
Enrichment class:
biological processes
downregulated by IL-28A
(p-value)
downregulated by IL-29
(p-value)
mRNA transcription regulation 1.261026 n. s.
Enrichment class:
molecular function
induced by IL-28A
(p-value)
induced by IL-29
(p-value)
Ligase 3.761026 8.261027
Ubiquitin protein ligase 8.661027 1.161026
Enrichment class:
molecular function
downregulated by IL-28A
(p-value)
induced by IL-29
(p-value)
Nucleic acid binding 1.361027 n. s.
Other DNA-binding protein 2.561029 n. s.
Homeobox transcription factor 2.361027 n. s.
In all classifications, p-values ,1025 vs. the distribution of all genes on the microarray chip were considered as significant enrichment. n.s.: not significant.
doi:10.1371/journal.pone.0015200.t005
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Figure 3. IL-28A and IL-29 induce OAS1 and MX1 mRNA expression and promoter activity in hepatic cells. (A) OAS1 mRNA expression is
increased by IL-28A and IL-29 stimulation of Huh-7 cells reaching maximal levels after 24 hours. Samples were analyzed by quantitative PCR in
triplicate for each group and were normalized to the expression in unstimulated cells. (B) IL-28A and IL-29 induce maximal MX1 mRNA expression
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measured total IL-28 and IL-29 mRNA levels in liver biopsies
(n = 28) from patients with HCV and other non-viral liver diseases.
IL-28 mRNA expression was highest in HCV patients (18.4-fold
vs. other liver diseases, p,0.05; Fig. 5A) and was detectable in
100% (9/9) of HCV biopsies but in only 58% (11/19) of biopsies
from non-HCV hepatitis (p,0.05; Fig. 5B). Similarly, IL-29
mRNA expression was highest in HCV patients (26.4-fold vs. non-
HCV liver diseases, p,0.05; Fig. 5A) and was detectable in 78%
(7/9) of HCV biopsies but in only 63% (12/19) of biopsies from
non-HCV hepatitis (Fig. 5B). In all biopsies, IL-28 and IL-29
mRNA expression correlated highly with each other (r = 0.892).
We then measured IL-28A serum protein concentration using
an immunoluminometric assay (ILMA) in another group of liver
disease patients, each comprising 15 patients with HCV or HBV
infection, primary sclerosing cholangitis (PSC), and 24 patients
with primary biliary cirrhosis (PBC) as well as 15 controls. IL-28A
serum protein levels were significantly higher in patients with viral
infection (mean concentrations of 52.2 pg/ml in HCV and
46.3 pg/ml in HBV patients) in comparison to non-viral liver
diseases such as PBC (mean concentration 14.9 pg/ml; p,0.01 vs.
HCV/HBV), PSC (mean concentration 21.2 pg/ml; p,0.05 vs.
HCV/HBV) or a control group (mean concentration 23.6 pg/ml;
p,0.05 vs. HCV/HBV) (Fig. 5C).
IL-28 mRNA expression is increased in the liver of murine
cytomegalovirus (MCMV)-infected mice
Given the current lack of a simple murine model for HCV
infection [29] and in order to analyze if the up-regulation of IFN-
ls in vivo can be found in viral liver disease other than HCV and
HBV, we studied IFN-l expression in murine cytomegalovirus
(MCMV) infection, an established model of murine viral hepatitis
[30,31]. Given that no IL-29 gene is known in mice, we solely
determined IL-28 mRNA expression levels 45 hours after
infection. Compared to non-infected mice (n = 4), IL-28 mRNA
expression was 2.7-fold higher in MCMV-infected mice (n = 10;
p,0.005; Fig. 6).
Discussion
This study represents the first detailed comparative investigation
of IL-28A- and IL-29-mediated biological activities and gene
expression patterns in viral hepatitis and non-viral liver disease in
vivo. We demonstrate that the IFN-l receptor complex is
functionally expressed in liver cells while IFN-lR1 is expressed
only at low levels in leukocytes. Both IL-28A and IL-29 are able to
induce STAT1 phosphorylation in hepatic cells with IL-29
showing slightly stronger effects. Our microarray analysis revealed
activation of mostly identical genes by IL-28A and IL-29. Among
them were numerous genes involved in interferon-mediated
immunity and antiviral defense, such as MX1 [32], OAS1, OAS3
and OASL [33], BST2 (tetherin) [34], inhibitors of protein synthesis
such as PKR [35], IFIT1 and IFIT2 [36], antiproliferative genes
like IFITM1 [37] and the Bcl-2-related proapoptotic gene APOL6
[38], TAP1 (involved in antigen processing and presentation) [39],
as well as other interferon-stimulated genes such as ISG15
(ubiquitin-like modifier) [33] or IFI6 (6–16 protein) [40]. A recent
study analyzing the effect of IL-29 in HepG2 cells revealed 35 up-
regulated genes following IL-29 stimulation [41]. Among these, 27
were found in our analysis of IL-28A as well as IL-29 confirming
the similarity between these two cytokines.
The analogy of IL-28A and IL-29 is further supported by the
fact that we observed no synergistic or additive effect of both
cytokines concerning the induction of gene expression. This
suggests common signaling pathways and functions of these
cytokines. Moreover, the dose of IFN-l used in this study (100 ng/
ml) seems to be a saturation concentration for this cytokine.
IFN-ls also increased mRNA expression of STAT1, STAT2
and IRF9 whose protein products together form the ISGF3
transcription factor complex characteristic for IFN type I and type
III signaling. ISGF3 in turn activates a number of IFN-stimulated
genes (ISG), thereby contributing to the antiviral response.
Similarly, a recent study showed that IL-29 stimulation also leads
to increased levels of total STAT1 and STAT2 protein and hence
to a prolonged induction of target genes [14].
Three additional genes with relevant immunological functions
which were up-regulated by IFN-ls included TLR3, MDA5
(IFIH1) and RIG-I (DDX58). The proteins belong to the pattern
recognition receptors (PRRs) of the innate immune system and
bind specifically extracellular derived dsRNA (TLR3) and
cytoplasmic viral RNA (MDA5, RIG-I) [42]. It has recently been
demonstrated that TLR3 ligands mediate an antiviral state against
HCV in hepatic cells [43] and induce antiviral activity of IFN-ls
[44]. RIG-I is likewise important for the antiviral state in HCV
infection [45]. On the other hand, HCV is able to inhibit several
PRR pathways [46], suggesting that up-regulation of PRR mRNA
expression by IL-28A and IL-29 might counteract this HCV-
mediated effect. In our study, IL-28A and IL-29 up-regulated a
Figure 4. IL-28A and IL-29 significantly decrease HCV replica-
tion. In luciferase assays with HCV replicon expressing cells, 10 or
100 ng/mL IL-28A or IL-29 strongly reduced HCV replication up to
84.8% and 87.7%, respectively, compared to untreated cells
(p,5610214; IFN-a: 72.5% reduction vs. untreated, p,5610213).
doi:10.1371/journal.pone.0015200.g004
after 9 hours of stimulation as determined by qPCR and normalized to untreated cells. (C) IL-28A and IL-29 do not act synergistically. OAS1 and MX1
gene induction by IL-28A and IL-29 alone (100 ng/ml) was not significantly different from treatment with both cytokines together (50 or 100 ng/ml
each) in Huh-7 cells. (D) Reporter gene assays and OAS1 luciferase construct revealed activation of the OAS1 promoter 5.1-fold (IL-28A) and 14.3-fold
(IL-29), respectively, and the MX1 promoter 2.4-fold (IL-28A) and 4.8-fold (IL-29), respectively, in HepG2 cells following stimulation for 6 hours with
100 ng/ml IL-28A or IL-29, respectively. IFN-a was used as a positive control. Baseline reporter gene activity was set as 1. IL-28A/IL-29 induced
reporter gene activity in all other groups was calculated as –fold increase in comparison to this control group. *p,0.05; **p,0.0005 vs. control.
doi:10.1371/journal.pone.0015200.g003
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Figure 5. Expression of IL-28A and IL-29 is significantly increased in human hepatitis C infection. (A) Total IL-28A/B expression in liver
biopsies from HCV patients (n = 9) is 18.4-fold higher in comparison to patients with other liver diseases such as primary sclerosing cholangitis, (PSC;
n = 2), primary biliary cholangitis (PBC; n = 2), autoimmune hepatitis (AIH; n = 2), non-alcoholic steatosis hepatis (NASH; n = 3), or hepatitis of unknown
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nearly identical gene transcription program which also resembles
that of IFN-a [41]. However, it has recently been demonstrated
that neither IFN-a nor IL-29 are able to down-regulate gene
expression in hepatic cells [16,17,41]. In concordance with these
previous studies [16,17,41], we measured no significant down-
regulation of genes following IL-29 stimulation.
Therefore, it is of great interest that in contrast IL-28A
significantly reduced the expression of 89 genes more than 2-fold
(adj.-p,0.05) in our experiments. This number was even higher
than the number of induced genes (65, adj.-p,0.05). Many of
these genes code for DNA-binding proteins and are involved in the
transcriptional regulation.
The activation of antiviral proteins by IL-28A and IL-29
tempted us to investigate the effect of IFN-ls on the replication
rate of HCV in an in vitro system expressing HCV replicons. In
these experiments, we demonstrated that both, IL-28A and IL-29
at a dose of 100 ng/ml reduce significantly the replication rate of
HCV with the same efficacy and comparable to IFN-a. However,
at a concentration of 10 ng/ml, IL-29 is 20% more effective in
inhibiting HCV replication than IL-28A (p,0.005). Currently, a
pegylated form of IL-29 is tested in a phase 1b clinical study in
HCV patients [47]. Preliminary results indicate that it is effective
in reducing viral load without typical side effects seen with IFN-a
[47] which may be related to the more restricted expression of the
IFN-l receptor subunit IFN-lR1 compared to the IFN-a receptor
subunits IFNAR1 and IFNAR2.
A recent study demonstrated that IL-28B appears to be the most
potent IFN-l cytokine, at least in EMCV infection [48]. However,
in VSV infection, IL-28B did not show any effect [48]. Moreover,
there were also considerable differences in specific activities
between the same cytokines derived from different sources [48]
indicating that the production and preparation methods are
crucial variables. Interestingly, several recent publications describe
an association between single nucleotide polymorphisms (SNPs) in
the IL28B gene region and the clearance of HCV infection, either
naturally occurring [49] or induced by treatment with a
combination therapy of IFN-a and ribavirin [50,51,52]. Some of
these SNPs are located in the IL28B gene itself while others are
situated upstream or downstream of IL28B [16,17,41,49]. The
functional consequences of the SNPs in the IL28B gene region are
not yet clear and need further investigations. Given that the IL28A
and IL28B genes lie in close proximity on chromosome 19q13.13,
it is possible that some of these SNPs influence regulatory elements
of both IL28A and IL28B [51]. This is supported by data
demonstrating lower IL-28A/B mRNA expression in whole blood
and PMBCs, respectively, in minor allele carriers and non-
responders to IFN-a therapy [51,52]. As IL28B mRNA is 98%
identical to IL28A mRNA and can hardly be distinguished from
the latter by PCR analysis, it cannot be excluded that IL-28A also
plays a major role in HCV viral clearance.
Furthermore, in our study, we measured increased expression of
IL-28 and IL-29 mRNA in the liver of patients infected with HCV
in comparison to non-viral liver disease. IFN-l mRNA was
detectable in only 60.5% of the biopsies of non-viral liver disease
but in 88.9% of the livers with HCV infection suggesting an
essential role of HCV in the regulation of IFN-l gene
transcription. Further studies need to determine if the IFN-l
upregulation has a significant influence on the clinical presentation
and the outcome of HCV infection. It may be hypothesized that
patients with higher intrinsic IFN-l expression show a better HCV
clearance. This hypothesis is supported by the fact that lower IL-
28A/B mRNA expression has been observed in non-responders to
IFN-a therapy [51,52]. Moreover, HCV patients with low
endogenous IFN-l expression might benefit more from a novel
treatment with pegylated IL-29 than those with high IFN-l levels.
The up-regulation of IFN-l gene expression has also been
described for other viral infections [1,2,8,15,53]. In contrast, the
study of Mihm et al. shows that IFN-l expression in the liver is
similar in non-viral liver disease and HCV infection [54]. This
difference to our study might be due to their small sample size in
the non-viral liver disease group (8 samples) which included one
outlier. However, there was a higher expression in HCV infection
in comparison to healthy control liver tissue [54]. Moreover, they
found higher IFN-l mRNA expression in PBMC of HCV patients
in comparison to healthy controls [54]. To our knowledge, IL-28A
protein concentration has not been measured previously in the
serum of HCV patients. Therefore, we developed an immunolu-
minometric assay which detected significantly higher IL-28A
protein expression levels in the serum of HCV- or HBV-infected
patients in comparison to healthy controls, but also in comparison
to non-viral liver disease such as PBC. This suggests that IL-28A
does not only have a ‘‘local’’ liver-specific role in the antiviral
defense but also modulates the systemic antiviral immune response
against HCV.
In further studies, it will be of great interest if the IL-28B-
mediated gene expression and repression in hepatic cells resembles
the pattern of IL-28A or IL-29 or is even different to both
Figure 6. IL-28 expression is increased in murine viral hepatic
infection. Mice were infected with 16106 pfu of murine cytomegalo-
virus for 45 hours. Quantitative PCR analysis demonstrated an increase
of IL-28 expression of 2.7-fold in comparison to not infected control
mice. * p,0.005 vs. not infected. No IL-29 gene has been described in
mice, therefore not allowing expression analysis of this cytokine.
doi:10.1371/journal.pone.0015200.g006
origin (HUO; n = 9) as determined by quantitative PCR. IL-29 expression was 26.4-fold higher in HCV vs. non-HCV biopsies (*p,0.05 vs. any other
group). (B) Detailed analysis of each single biopsy reveals expression of total IL-28 in all 9 out of 9 HCV patients ( = number marked by an asterisk)
while in 8 out of 19 non-HCV biopsies, IL-28 could not be detected after 40 PCR cycles ({= IL-28 not detectable; p,0.05). IL-29 was expressed in 7 out
of 9 HCV biopsies and in 12 out of 19 non-HCV biopsies (#= IL-29 not detectable). (C) Analysis of IL-28A serum levels in liver disease patients and
controls by an IL-28A-specific ILMA demonstrated significantly higher IL-28A protein expression in the sera of HBV and HCV patients in comparison to
controls or PBC patients (*p,0.05; n = 15 in each group [except PBC: n = 24]).
doi:10.1371/journal.pone.0015200.g005
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cytokines. Further investigations should elucidate if the different
abilities of IL-28A and IL-29 to repress gene transcription have
functional consequences in HCV infection in vivo as the replicon
system represents only one single aspect of HCV life cycle. In
addition, it will be of interest if these differences have practical
impact in other viral infections in vivo, but also for the treatment of
other diseases such as cancer. Given their ability to inhibit
proliferation and to induce apoptosis [8,55], IFN-ls have been
also been discussed as a future cancer treatment option.
In summary, we have shown that both IL-28A and IL-29 induce
expression of antiviral proteins, inhibit HCV replication and are
up-regulated during viral infection with no major differences.
However, in contrast to IL-29, IL-28A has the capacity to repress
gene expression. Both cytokines are promising candidates for the
treatment of HCV infection with likely low side effects on
leukocytes. Nevertheless, further studies are needed to clarify
which of the three IFN-l cytokines is the most potent with the least
amount of side effects.
Supporting Information
Figure S1 Functional categorization of IL-28A and IL-29
induced gene expression. In all classifications, p-values,1025
vs. the distribution of all genes on the microarray chip were
considered as significant enrichment. Main classification groups
are depicted in bold letters, while subgroups are written with
normal letters. (A) Following IL-28A and IL-29 stimulation, genes
of the biological processes of immunity and defense (with its
subgroup interferon-mediated immunity) are significantly en-
riched. Proteolysis gene expression is significantly enriched only
by IL-28A. In the legend, the classes are listed in a clock-wise
order, starting at the ‘‘12 o’clock’’ position. (B) IL-28A and IL-29
both significantly enrich genes with the molecular functions of
ligases, especially ubiquitin protein ligases. In the legend, the
classes are listed in a clock-wise order, starting at the ‘‘12 o’clock’’
position.
(TIF)
Figure S2 Functional categorization of IL-28A repressed
gene expression. (A) In IL-28A-treated samples, the down-
regulated genes are enriched in the biological process of mRNA
transcription regulation (for color chart legend, see Figure S1A).
IL-29 did not down-regulate genes significantly (data not shown).
(B) The molecular functions of IL-28A down-regulated genes
comprise mainly of nucleic acid binding proteins and of homeobox
transcription factors (for color chart legend, see Figure S1B).
(TIF)
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